The next generation of biotech blockbusters

The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, these biologics could receive FDA approval this year if they don't hit any stumbling blocks. Each of the drugs on this list has the potential for over a billion dollars in sales if all goes according to plan. These four drugs are the next generation of biologic blockbusters that could offer real breakthroughs for patients--and add significant cash to their developers' bottom lines.

Motavizumab - AstraZeneca's MedImmune

Denosumab - Amgen

Golimumab - Johnson & Johnson's Centocor

Ipilimumab - Bristol-Myers Squibb, Medarex

Data courtesy of IMS Health


Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.